ReNeuron Group plc Block Listing Review and TVR (3082G)

TIDMRENE

RNS Number : 3082G

ReNeuron Group plc

01 March 2018

 
 1 March 2018   AIM: RENE 
 

ReNeuron Group plc

Block Listing Review and Total Voting Rights

ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements.

 
 Name:                         ReNeuron Group plc 
----------------------------  ------------------------ 
 Name of Scheme:               ReNeuron Share Option 
                                Schemes 
----------------------------  ------------------------ 
 Period of Return:             From 1 September 2017 
                                to 28 February 2018 
----------------------------  ------------------------ 
 Balance of unallotted         902,825 Ordinary Shares 
  securities under scheme(s)    (of 1p each) 
  from previous return: 
----------------------------  ------------------------ 
 Plus: The amount by           N/A 
  which the block scheme(s) 
  has been increased 
  since the date of 
  the last Review (if 
  any increase has been 
  applied for): 
----------------------------  ------------------------ 
 Less: Number of securities 
  issued/allotted under          N/A 
  scheme(s) during period 
----------------------------  ------------------------ 
 Equals: Balance under         902,825 Ordinary Shares 
  scheme(s) not yet 
  issued/allotted at 
  end of period: 
----------------------------  ------------------------ 
 Number and class of           20,000 ordinary shares 
  securities originally         on 13 May 2010(1) 
  admitted and the date 
  of admission: 
----------------------------  ------------------------ 
 

(1) The original number and class of securities originally admitted on 13 May 2010 was 2,000,000 ordinary shares. Following the Reorganisation the Company has revised this disclosure to 20,000 Ordinary Shares and, where appropriate, will use this number within the Company's Block Listing Review disclosure going forwards.

Share Capital Consolidation

As previously announced, the Company has undertaken a 1 for 100 share capital consolidation (the "Reorganisation"), in the six-month period since the Company's last block listing update of 1 September 2017. Immediately prior to the Reorganisation the Company had 90,282,511 unallotted shares under its original block-listing scheme. Following the Reorganisation an application was made to the London Stock Exchange plc, for the admission to trading on AIM, of a replacement block listing of 902,825 new ordinary shares of 1p each in the capital of the Company ("Ordinary Shares"). As a result of the Reorganisation and the replacement block admission there are now 902,825 unallotted Ordinary Shares under the Scheme.

Total Voting Rights

The Company has 31,646,186 Ordinary Shares in issue, all with voting rights. The Company holds no Ordinary Shares in treasury. The figure of 31,646,186 Ordinary Shares may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.

ENDS

ENQUIRIES:

 
ReNeuron                                                                  [phone] 
Olav Hellebø , Chief Executive Officer 
Michael Hunt, Chief Financial Officer 
Buchanan                                                                  [phone] 
Mark Court, Sophie Wills, Stephanie Watson 
 
Stifel Nicolaus Europe Limited                                            [phone] 
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker) 
Nplus1 Singer Advisory LLP                                                [phone] 
Mark Taylor (Joint Broker) 
 

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise be unable to reach their site of action.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCBRGDDISDBGII

(END) Dow Jones Newswires

March 01, 2018 02:00 ET (07:00 GMT)